Abstract
The functional connection between activation of a single G protein-coupled receptor (GPCR) and a specific physiological outcome may be obscured by the presence of other closely related members of the GPCR superfamily that share spatiotemporal patterns of expression and equipotent activation by endogenous ligands. To address this issue, molecular and chemical genetic techniques have been developed to generate mutationally modified GPCRs only susceptible to activation by one or more synthetic ligands that are inactive at the equivalent wild-type receptor. This chapter provides both an overview of strategies used to generate such “receptors activated solely by synthetic ligands” (RASSLs) and, in more detail, approaches that have been used to assess the equivalence or otherwise of function of a wild-type and corresponding RASSL receptor. The human muscarinic M3 acetylcholine receptor is used as the exemplar but similar preliminary studies should be employed before further use, particularly in vivo, of such RASSLs.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- BAL:
-
2,3-Dimercapto-1-propanol
- BRET:
-
Bioluminescence resonance energy transfer
- CFP:
-
Cyan fluorescent protein
- CNO:
-
Clozapine N-oxide
- DREADD:
-
Designer receptor exclusively activated by designer drugs
- EDT:
-
2-Ethanedithiol
- FRET:
-
Fluorescence resonance energy transfer
- Fura-2AM:
-
Fura-2 acetoxymethyl ester
- GFP:
-
Green fluorescent protein
- GPCR:
-
G protein-coupled receptor
- IL3:
-
Third intracellular loop
- IP1:
-
Inositol monophosphate
- RASSL:
-
Receptor activated solely by synthetic ligands
- TMD:
-
Transmembrane domain
- YFP:
-
Yellow fluorescent protein
References
Digby GJ, Shirey JK, Conn PJ (2010) Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 6(8):1345–1354
Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44:423–450
Kruse AC, Hu J, Kobilka BK, Wess J (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24–30
Haga K et al (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482(7386):547–551
Kow RL, Nathanson NM (2012) Structural biology: Muscarinic receptors become crystal clear. Nature 482(7386):480–481
Kruse AC et al (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482(7386):552–556
McKinney M, Jacksonville MC (2005) Brain cholinergic vulnerability: relevance to behavior and disease. Biochem Pharmacol 70(8):1115–1124
Wess J (2012) Novel muscarinic receptor mutant mouse models. Handb Exp Pharmacol 208:95–117
Wess J et al (2003) M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 9(4):279–290
Conklin BR et al (2008) Engineering GPCR signaling pathways with RASSLs. Nat Methods 5(8):673–678
Coward P et al (1998) Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci U S A 95(1):352–357
Pei Y, Dong S, Roth BL (2010) Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution. Curr Protoc Neurosc 50: 4.33.1–4.33.25
Dong S, Rogan SC, Roth BL (2010) Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc 5(3):561–573
Hudson BD et al (2012) Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J 26(12):4951–4965
Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A 104(12):5163–5168
Strader CD et al (1991) Allele-specific activation of genetically engineered receptors. J Biol Chem 266(1):5–8
Strader CD, Sigal IS, Dixon RA (1989) Genetic approaches to the determination of structure-function relationships of G protein-coupled receptors. Trends Pharmacol Sci Suppl:26–30
Sartania N, Appelbe S, Pediani JD, Milligan G (2007) Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric beta2-adrenoceptor. Cell Signal 19(9):1928–1938
Campbell JH, Lengyel JA, Langridge J (1973) Evolution of a second gene for beta-galactosidase in Escherichia coli. Proc Natl Acad Sci U S A 70(6):1841–1845
Price LA, Kajkowski EM, Hadcock JR, Ozenberger BA, Pausch MH (1995) Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway. Mol Cell Biol 15(11):6188–6195
Pausch MH et al (1998) Heterologous G protein-coupled receptors expressed in Saccharomyces cerevisiae: methods for genetic analysis and ligand Identification and Expression of G protein-coupled Receptors, (196–212) Ed. Wiley-Liss, New York
Erlenbach I et al (2001) Functional expression of M-1, M-3, and M-5 muscarinic acetylcholine receptors in yeast. J Neurochem 77(5):1327–1337
Olianas MC, Maullu C, Onali P (1999) Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20(3):263–270
Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology (Berl) 178(4):451–460
Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25:366–428
Han SJ et al (2005) Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. J Biol Chem 280(41):34849–34858
Han SJ et al (2005) Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor. J Biol Chem 280(26):24870–24879
Ferguson SM et al (2011) Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci 14(1):22–24
Alexander GM et al (2009) Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63(1):27–39
Mayford M et al (1996) Control of memory formation through regulated expression of a CaMKII transgene. Science 274(5293):1678–1683
Swaminath G et al (2005) Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280(23):22165–22171
Kobilka BK, Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28(8):397–406
Bhattacharya S, Hall SE, Li H, Vaidehi N (2008) Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. Biophys J 94(6):2027–2042
Alvarez-Curto E et al (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol 80(6):1033–1046
Alvarez-Curto E, Ward RJ, Pediani JD, Milligan G (2010) Ligand regulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogeneous time-resolved FRET. J Biol Chem 285(30):23318–23330
Lohse MJ, Bunemann M, Hoffmann C, Vilardaga JP, Nikolaev VO (2007) Monitoring receptor signaling by intramolecular FRET. Curr Opin Pharmacol 7(5):547–553
Lohse MJ et al (2008) Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol 153(Suppl 1):S125–S132
Maier-Peuschel M et al (2010) A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation. J Biol Chem 285(12):8793–8800
Zurn A et al (2009) Fluorescence resonance energy transfer analysis of alpha 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 75(3):534–541
Xu TR, Ward RJ, Pediani JD, Milligan G (2011) The orexin OX(1) receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands. Biochem J 439(1):171–183
Vilardaga JP (2011) Studying ligand efficacy at G protein-coupled receptors using FRET. Methods Mol Biol 756:133–148
Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S (2006) Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res 99(10):1084–1091
Hoffmann C et al (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods 2(3):171–176
Adams SR et al (2002) New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc 124(21):6063–6076
Griffin BA, Adams SR, Tsien RY (1998) Specific covalent labeling of recombinant protein molecules inside live cells. Science 281(5374):269–272
Martin BR, Giepmans BN, Adams SR, Tsien RY (2005) Mammalian cell-based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity. Nat Biotechnol 23(10):1308–1314
Hoffmann C et al (2010) Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat Protoc 5(10):1666–1677
Alvarez-Curto E, Pediani JD, Milligan G (2010) Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. Anal Bioanal Chem 398(1):167–180
Yang F, Moss LG, Phillips GN Jr (1996) The molecular structure of green fluorescent protein. Nat Biotechnol 14(10):1246–1251
Ormo M et al (1996) Crystal structure of the Aequorea victoria green fluorescent protein. Science 273(5280):1392–1395
Ziegler N, Batz J, Zabel U, Lohse MJ, Hoffmann C (2011) FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors. Bioorg Med Chem 19(3):1048–1054
Wess J, Maggio R, Palmer JR, Vogel Z (1992) Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J Biol Chem 267(27):19313–19319
Poulin B et al (2010) The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A 107(20):9440–9445
Tobin AB, Butcher AJ, Kong KC (2008) Location, location, location…site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 29(8):413–420
Butcher AJ, Tobin AB, Kong KC (2011) Examining site-specific GPCR phosphorylation. Methods Mol Biol 746:237–249
Gurevich VV, Gurevich EV (2004) The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 25(2):105–111
Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308(5721):512–517
Lefkowitz RJ, Whalen EJ (2004) beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol 16(2):162–168
Whalen EJ, Rajagopal S, Lefkowitz RJ (2011) Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 17(3):126–139
Shukla AK (2014) Biasing GPCR signaling from inside. Sci Signal 7(310):pe3
Verkaar F et al (2008) G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors. Biotechnol Annu Rev 14:253–274
Gautier A et al (2008) An engineered protein tag for multiprotein labeling in living cells. Chem Biol 15(2):128–136
Ward RJ, Pediani JD, Milligan G (2011) Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem 286(43):37414–37428
Hamdan FF, Audet M, Garneau P, Pelletier J, Bouvier M (2005) High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 10(5):463–475
Kocan M, Pfleger KD (2009) Detection of GPCR/beta-arrestin interactions in live cells using bioluminescence resonance energy transfer technology. Methods Mol Biol 552:305–317
Kocan M, Dalrymple MB, Seeber RM, Feldman BJ, Pfleger KD (2010) Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and beta-arrestins. Front Endocrinol 1:12
Kocan M, See HB, Seeber RM, Eidne KA, Pfleger KD (2008) Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J Biomol Screen 13(9):888–898
Jenkins L et al (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther 343(3):683–695
Rogan SC, Roth BL (2011) Remote control of neuronal signaling. Pharmacol Rev 63(2):291–315
Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28(8):390–396
Violin JD, Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28(8):416–422
Vaidehi N, Kenakin T (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10(6):775–781
Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9(5):373–386
Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336(2):296–302
Smith NJ, Bennett KA, Milligan G (2011) When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 331(2):241–247
Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16(8):869–871
Garner AR et al (2012) Generation of a synthetic memory trace. Science 335(6075):1513–1516
Zhu H et al (2014) Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory. Neuropsychopharmacology 39(8):1880–1892
Park JS et al (2014) Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A 111(16):5896–5901
Sasaki K et al (2011) Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS One 6(5), e20360
Krashes MJ et al (2011) Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest 121(4):1424–1428
Wess J, Nakajima K, Jain S (2013) Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci 34(7):385–392
Guettier JM et al (2009) A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A 106(45):19197–19202
Nakajima K, Wess J (2012) Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol 82(4):575–582
Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF (2006) The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc 2:145–161
Ferre S et al (2014) G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 66(2):413–434
Patowary S et al (2013) The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochem J 452(2):303–312
Pellissier LP et al (2011) G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient. J Biol Chem 286(12):9985–9997
Claeysen S, Donneger R, Giannoni P, Gaven F, Pellissier LP (2013) Serotonin type 4 receptor dimers. Methods Cell Biol 117:123–139
Herrick-Davis K, Grinde E, Harrigan TJ, Mazurkiewicz JE (2005) Inhibition of serotonin 5-hydroxytryptamine2c receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein. J Biol Chem 280(48):40144–40151
Herrick-Davis K (2013) Functional significance of serotonin receptor dimerization. Exp Brain Res 230(4):375–386
Gaven F et al (2013) Pharmacological profile of engineered 5-HT(4) receptors and identification of 5-HT(4) receptor-biased ligands. Brain Res 1511:65–72
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Alvarez-Curto, E., Milligan, G. (2015). Defining the Functional Equivalence of Wild-Type and Chemically Engineered G Protein-Coupled Receptors. In: Thiel, G. (eds) Designer Receptors Exclusively Activated by Designer Drugs. Neuromethods, vol 108. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2944-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2944-3_1
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2943-6
Online ISBN: 978-1-4939-2944-3
eBook Packages: Springer Protocols